Drug Profile
Research programme: glucose metabolism therapeutics - XOMA
Alternative Names: Insulin receptor-regulating antibodies - XOMA; X 129; XMet program; XMetA; XMetD; XMetD antibody fragment (Fab); XMetS; XOMA-129Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator XOMA
- Class Antihypoglycaemics; Monoclonal antibodies
- Mechanism of Action Insulin receptor agonists; Insulin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 1 diabetes mellitus; Type 2 diabetes mellitus
Highest Development Phases
- No development reported Diabetes mellitus; Hypoglycaemia
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Hypoglycaemia in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Parenteral)
- 01 Apr 2017 Pharmacodynamics data from preclinical studies in Hypoglycaemia presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)